Asaf Danziger, Chief Executive Officer at NovoCure Ltd (NVCR), sold 200,000 shares at $56.49 ($11.1M) on 2019-03-01, disclosed to the SEC on 2019-03-04.
Open-market sale of $11.1M NVCR by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.97 | 37,282 | $2.0M | 18.4% |
| 2 | $54.97 | 37,282 | $2.0M | 18.4% |
| 3 | $55.85 | 55,815 | $3.1M | 28.1% |
| 4 | $55.85 | 55,815 | $3.1M | 28.1% |
| 5 | $56.49 | 6,903 | $390K | 3.5% |
| 6 | $56.49 | 6,903 |
| $390K |
| 3.5% |
| Total | $55.57 avg | 200,000 | $11.1M | 100% |
| Filing → |
| NVCR | SELL | 2021-04-15 | $38.5M | — | Filing → |
| NVCR | SELL | 2020-12-22 | $61.4M | — | Filing → |
| NVCR | SELL | 2020-09-17 | $10.2M | — | Filing → |